Spyre Therapeutics, Inc. Common Stock (SYRE) is a publicly traded Healthcare sector company. As of May 21, 2026, SYRE trades at $71.70 with a market cap of $6.09B and a P/E ratio of 0.00. SYRE moved +7.99% today. Year to date, SYRE is +140.05%; over the trailing twelve months it is +367.01%. Its 52-week range spans $10.91 to $78.80. Analyst consensus is strong buy with an average price target of $95.86. Rallies surfaces SYRE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Spyre Therapeutics climbs as Q1 update boosts runway and 2026 data-readout focus: Spyre Therapeutics shares rose after the company reported Q1 2026 results on May 5, 2026 and reiterated multiple 2026–2027 clinical readouts. The update highlighted an expected cash runway into the second half of 2029, supporting sentiment as traders position ahead of upcoming data.
| Metric | Value |
|---|---|
| Price | $71.70 |
| Market Cap | $6.09B |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $78.80 |
| 52-Week Low | $10.91 |
| Volume | 628 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-155.20M |
| Gross Margin | 0.00% |
16 analysts cover SYRE: 0 strong buy, 16 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $95.86.